Personalized Care with DPP4i/SGLT2i Strategy as Initial-Line in the Management of Type 2 Diabetes Mellitus with Cardiovascular Risk: DELPHI Statement. Cardiology and Cardiovascular Medicine, v. 8, n. 2, p. 111–117, 28 Mar.2024.